<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antiulcer medications: Mechanism of action, pharmacology, and side effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antiulcer medications: Mechanism of action, pharmacology, and side effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antiulcer medications: Mechanism of action, pharmacology, and side effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nimish B Vakil, MD, AGAF, FACP, FACG, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H23613455">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eradication of
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ), withdrawal of nonsteroidal anti-inflammatory drugs (NSAIDs), and antisecretory drugs are the mainstays of treatment for peptic ulcer disease.
        </p>
        <p>
         The pharmacology of antiulcer drugs, excluding the antibiotics used to treat
         <em>
          H. pylori
         </em>
         , will be reviewed here. For detailed prescribing information, readers should refer to the individual drug information topics within UpToDate. Comprehensive information on drug-drug interactions can be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         . This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. Complete information on US Food and Drug Administration (FDA) labeling for each drug can be accessed using the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fscience-research%2Fbioinformatics-tools%2Ffdalabel-full-text-search-drug-product-labeling&amp;token=IMdkTPwjShZ0l3qxBMG5QAteHI69f3HgTNUs5uh4k8edmwHeth141Xv%2BbYJlHvyTvnag7gCX7gwVmzBuR6ByX2zBO1sQKNbkGTCSUO0%2FjSODsFdgYy%2FC%2FbUDMfhadJwb&amp;TOPIC_ID=32" target="_blank">
          FDA searchable database
         </a>
         .
        </p>
        <p>
         Treatment regimens for
         <em>
          H. pylori
         </em>
         and management of peptic ulcer disease are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9880098">
         <span class="h1">
          ANTISECRETORY AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Histamine-2 receptor antagonists
         </span>
        </p>
        <p class="headingAnchor" id="H2939398644">
         <span class="h3">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histamine-2 receptor antagonists (H2RAs) (eg,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9708" href="/z/d/drug information/9708.html" rel="external">
          nizatidine
         </a>
         ) inhibit acid secretion by blocking H2 receptors on the parietal cell  (
         <a class="graphic graphic_figure graphicRef57131" href="/z/d/graphic/57131.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         H2RAs are well absorbed after oral dosing; peak serum concentrations occur within one to three hours. Absorption is reduced 10 to 20 percent by concomitant antacid administration, but not by food.
        </p>
        <p>
         H2RAs are eliminated by a combination of hepatic and renal metabolism [
         <a href="#rid1">
          1
         </a>
         ]. Their bioavailability is reduced 30 to 70 percent by first-pass hepatic metabolism [
         <a href="#rid1">
          1
         </a>
         ]. Renal clearance is generally greater than accounted for by glomerular filtration, reflecting the importance of renal tubular secretion [
         <a href="#rid1">
          1
         </a>
         ]. The dose of all the H2RAs is generally reduced by 50 percent in patients with severe renal failure [
         <a href="#rid1">
          1-3
         </a>
         ]. The half-life of
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         is prolonged with liver failure, but dose reduction is necessary only if renal failure accompanies severe hepatic disease [
         <a href="#rid1">
          1,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Side effects of H2RAs are rare [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gynecomastia and impotence
         </strong>
         – Gynecomastia and impotence occur with
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         in a dose- and time-dependent fashion and resolve when discontinued [
         <a href="#rid6">
          6
         </a>
         ]. This effect is relatively specific for cimetidine and rarely occurs if treatment is limited to standard doses for eight weeks or less [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematopoietic and immune effects
         </strong>
         – Long-term H2RA use is also associated with B12 deficiency [
         <a href="#rid8">
          8
         </a>
         ]. H2RAs have also been implicated in idiosyncratic cases of myelosuppression, thrombocytopenia, neutropenia, anemia, and pancytopenia [
         <a href="#rid9">
          9-13
         </a>
         ]. Other rare diseases that have been associated with H2RAs include polymyositis and interstitial nephritis, an immune complex rash, and fever [
         <a href="#rid9">
          9,14,15
         </a>
         ]. Some immunomodulatory effects may reflect a unique action of the imidazole ring of
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         rather than actions at H2 receptors [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system (CNS) effects
         </strong>
         – H2RAs have been associated with CNS side effects including confusion, restlessness, somnolence, agitation, headaches, dizziness, and, with prolonged therapy, hallucinations, focal twitching, and seizures [
         <a href="#rid13">
          13,14,16
         </a>
         ]. Although these symptoms are generally reversible upon discontinuation of the drug, cases with more persistent CNS symptoms have been reported [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Mental status changes appear to be most common in older adults in the intensive care unit with renal or hepatic dysfunction and are rare in outpatients [
         <a href="#rid16">
          16,18
         </a>
         ].
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          Cimetidine
         </a>
         has been implicated as the most frequent cause of these CNS symptoms, but similar side effects have also been described with
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         [
         <a href="#rid14">
          14,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic effects
         </strong>
         – H2RAs are metabolized in the liver by the cytochrome P450 system. Of the H2RAs,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         is the most potent inhibitor of the P450 system (CYP1A2, 2C9, and 2D6) and can cause significant drug interactions. H2RAs can rarely cause acute hepatic injury [
         <a href="#rid4">
          4,19,20
         </a>
         ]. The clinical presentation of the hepatic injury may be cholestatic, hepatocellular, or mixed with features of both cholestatic and hepatocellular injury [
         <a href="#rid20">
          20
         </a>
         ]. Patients may rarely have features of hypersensitivity with rash, fever, and/or eosinophilia. The acute hepatitis is rapidly reversible after withdrawal of the drug. Hepatotoxicity has recurred with rechallenge in a sufficient number of cases to firmly establish this rare, but important, association [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">
          "Drug-induced liver injury", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac effects
         </strong>
         – Sinus bradycardia, hypotension, atrioventricular block, prolongation of the QT interval, and sinus and cardiac arrest have occurred with the rapid infusion of an H2RA [
         <a href="#rid1">
          1,21,22
         </a>
         ]. Oral therapy also has been reported to cause cardiac toxicity, although clinically significant effects upon sinus rhythm or conduction are rare. Possible risk factors for cardiac events include rapid intravenous infusion, high dose, conditions that would delay drug clearance (eg, renal or hepatic dysfunction), and underlying cardiac disease [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal effects
         </strong>
         – Mild increases in serum creatinine have been observed with
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         . However, immune-mediated interstitial nephritis is rare [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Contamination with nitrosodimethylamine (NDMA), a probable human carcinogen, has been found in
         <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">
          ranitidine
         </a>
         . This has led to its withdrawal by the US Food and Drug Administration (FDA) [
         <a href="#rid23">
          23
         </a>
         ]. NDMA impurities were found to have been introduced during the manufacturing processes and as the result of product degradation during storage. The FDA's testing has not found NDMA in
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         and
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Proton pump inhibitors
         </span>
        </p>
        <p class="headingAnchor" id="H3590098520">
         <span class="h3">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The proton pump inhibitors (PPIs) (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9074" href="/z/d/drug information/9074.html" rel="external">
          dexlansoprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         ) effectively block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane  (
         <a class="graphic graphic_figure graphicRef57131" href="/z/d/graphic/57131.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p>
         A complete discussion of the pharmacology, clinical efficacy, and safety of the PPIs is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3816583453">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse effects of PPIs are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1041628715">
         <span class="h2">
          Indications and comparative efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a result of stronger acid suppression as compared with H2RA, PPI use results in faster control of peptic ulcer disease symptoms and higher ulcer healing rates [
         <a href="#rid24">
          24-27
         </a>
         ]. PPIs are also more effective in preventing nonsteroidal anti-inflammatory drug (NSAID)-induced gastroduodenal toxicity and in healing gastroduodenal ulcers associated with NSAIDs when they cannot be discontinued [
         <a href="#rid28">
          28
         </a>
         ]. PPIs are a component of
         <em>
          H. pylori
         </em>
         antibiotic regimens and are used in the treatment of hypersecretory states (eg, gastrinoma). (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Indications for PPI therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">
          "Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults", section on 'Initial antibiotic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         .)
        </p>
        <p>
         Unlike H2RAs, tolerance does not occur for PPIs, but variable PPI metabolism may account for some difference in efficacy. (See
         <a class="medical medical_review" href="/z/d/html/33.html" rel="external">
          "Physiology of gastric acid secretion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          ANTACIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antacids usually contain a combination of magnesium trisilicate,
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3772337587">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antacids can neutralize gastric acid and reduce acid delivery to the duodenum. The following are hypothesized mechanisms for the acid-independent actions of antacids; however it is unclear which, if any, of these actions facilitate peptic ulcer healing [
         <a href="#rid29">
          29,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          Aluminum hydroxide
         </a>
         binds growth factors and enhances their binding to experimental ulcers, possibly serving to deliver growth factors to injured mucosa.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antacids promote angiogenesis in injured mucosa [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antacids bind bile acids and also inhibit peptic activity [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heavy metals are well known to suppress, but generally not eradicate,
         <em>
          H. pylori
         </em>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3946093831">
         <span class="h2">
          Indication
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the effectiveness of proton pump inhibitors (PPIs), antacids are not used in the treatment of peptic ulcer disease. The role of antacids is limited to the treatment of heartburn associated with mild intermittent gastroesophageal reflux disease. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Antacids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2158110674">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antacid side effects depend upon the quantity consumed and the duration of therapy. Magnesium-containing antacids cause diarrhea and hypermagnesemia; the latter only becomes important in patients with renal insufficiency. Some antacids may also contain sodium, and volume overload can occur in susceptible patients.
        </p>
        <p>
         Ingestion of large amounts of calcium and absorbable alkali, particularly
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         , can lead to hypercalcemia, alkalosis, and acute or chronic renal injury, a constellation known as the milk-alkali syndrome [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/827.html" rel="external">
          "The milk-alkali syndrome"
         </a>
         .)
        </p>
        <p>
         Significant aluminum retention only occurs in patients with renal failure and may result in neurotoxicity and anemia following prolonged treatment with
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         . Aluminum hydroxide blocks intestinal absorption of phosphate; two weeks of therapy with moderate doses can result in significant hypophosphatemia, especially if the patient is on a low phosphate diet or is phosphate depleted for other reasons [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease", section on 'Other medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUCRALFATE
         </span>
        </p>
        <p class="headingAnchor" id="H1070457384">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          Sucralfate
         </a>
         is a sulfated polysaccharide, sucrose octasulfate, complexed with
         <a class="drug drug_general" data-topicid="8499" href="/z/d/drug information/8499.html" rel="external">
          aluminum hydroxide
         </a>
         . It prevents acute, chemically-induced mucosal damage and heals chronic ulcers without altering gastric acid or pepsin secretion or significantly buffering acid [
         <a href="#rid29">
          29,35
         </a>
         ]. Similar to aluminum-containing antacids, sucralfate stimulates angiogenesis and the formation of granulation tissue, possibly due to growth factor binding [
         <a href="#rid29">
          29
         </a>
         ]. Sucralfate also binds to the injured tissue, thereby delivering growth factors and reducing access to pepsin and acid. Aluminum hydroxide mediates some of the actions of sucralfate, but the sucrose octasulfate moiety may also have a role by contributing sulfhydryl groups to reduce oxidant damage to epithelial cells.
        </p>
        <p class="headingAnchor" id="H1463462738">
         <span class="h2">
          Indication
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          Sucralfate
         </a>
         has been reported to suppress
         <em>
          H. pylori
         </em>
         and inhibit acid secretion in infected patients with duodenal ulcers [
         <a href="#rid36">
          36
         </a>
         ]. However, sucralfate is not used to treat peptic ulcers as proton pump inhibitors (PPIs) heal ulcers more rapidly and to a greater extent [
         <a href="#rid37">
          37
         </a>
         ]. The use of sucralfate is limited to the initial management of gastroesophageal reflux disease in pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Pregnancy and lactation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          Sucralfate
         </a>
         has few adverse effects [
         <a href="#rid35">
          35
         </a>
         ]. It can bind to other drugs if taken simultaneously. Similar to antacids, significant aluminum retention only occurs in patients with renal failure [
         <a href="#rid3">
          3,38,39
         </a>
         ]. Sucralfate can also bind to phosphate and lead to hypophosphatemia [
         <a href="#rid40">
          40
         </a>
         ]. Combining sucralfate and antacids can potentially amplify these effects. (See
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/830.html" rel="external">
          "Hypophosphatemia: Causes of hypophosphatemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          BISMUTH
         </span>
        </p>
        <p class="headingAnchor" id="H1936237927">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bismuth does not inhibit or neutralize gastric acid. The most dramatic action of bismuth salts is the suppression of
         <em>
          H. pylori
         </em>
         [
         <a href="#rid41">
          41
         </a>
         ]. Other actions that may promote ulcer healing include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibition of peptic activity but not pepsin secretion [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bismuth from colloidal bismuth subcitrate (CBS) may bind to ulcer craters [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrophages, recruited to the edge of the ulcer crater in CBS-treated rats, may promote healing [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CBS may increase mucosal prostaglandin production and mucus and bicarbonate secretion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2023657798">
         <span class="h2">
          Indication
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of bismuth preparations (eg, bismuth subcitrate and
         <a class="drug drug_general" data-topicid="101044" href="/z/d/drug information/101044.html" rel="external">
          bismuth subsalicylate
         </a>
         [BSS]) is limited to part of a quadruple antibiotic therapy regimen in
         <em>
          H. pylori-
         </em>
         positive ulcers [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults", section on 'Bismuth quadruple therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the colon, bismuth salts react with hydrogen sulfide to form bismuth sulfide, which blackens the stools [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Bismuth toxicity is rare with CBS or BSS [
         <a href="#rid41">
          41,46
         </a>
         ]. Bismuth absorption varies with the specific form of bismuth; absorption is much greater with CBS than with BSS or bismuth subnitrate [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         Coadministration of histamine-2 receptor antagonists (H2RAs) increases bismuth absorption from CBS, but not from BSS or bismuth subnitrate [
         <a href="#rid49">
          49
         </a>
         ]. Bismuth should be avoided or serum bismuth concentrations monitored in patients with renal failure [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The subsalicylate moiety in BSS is converted to salicylic acid and absorbed; however, salicylate in the absence of the acetyl group does not inhibit platelet function or appear to share the same high risk of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for gastrointestinal bleeding [
         <a href="#rid50">
          50-53
         </a>
         ]. However, the salicylate from BSS will raise serum salicylate levels and can cause salicylate toxicity, and combination with other salicylate products should therefore be avoided.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          MISOPROSTOL
         </span>
        </p>
        <p class="headingAnchor" id="H3324380605">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          Misoprostol
         </a>
         is a 15-deoxy-15-hydroxy-16-methyl analogue of prostaglandin E1. Prostaglandins, particularly of the E and I group, inhibit acid secretion by selectively reducing the ability of the parietal cell to generate cyclic adenosine monophosphate in response to histamine [
         <a href="#rid54">
          54
         </a>
         ]. Prostaglandins also enhance mucosal defense mechanisms [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity", section on 'Misoprostol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3912946929">
         <span class="h2">
          Indication
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         in peptic ulcer disease is limited to the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastroduodenal ulcers. It is contraindicated in women of childbearing potential who are not on contraception. (See
         <a class="local">
          'Pregnancy and lactation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most frequent side effects of
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         are dose-dependent cramping, abdominal pain, and diarrhea [
         <a href="#rid56">
          56,57
         </a>
         ]. These side effects interfere with compliance in many patients. (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity", section on 'Misoprostol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1072317995">
         <span class="h1">
          POTASSIUM-COMPETITIVE ACID INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potassium-competitive acid inhibitors (PCABs) work by competing for potassium on the luminal side of the parietal cell, and cause rapid and reversible inhibition of pumps and therefore acid secretion [
         <a href="#rid58">
          58
         </a>
         ]. After oral doses, PCABs rapidly achieve high plasma concentrations and have linear, dose-dependent pharmacokinetics; therefore, they have a rapid onset of action and achieve a full effect with the first dose. The effect is also seen with repeated doses.
        </p>
        <p>
         PCABs are not available outside of Asia [
         <a href="#rid59">
          59-62
         </a>
         ]. In randomized controlled trials, the efficacy with regard to ulcer healing and prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers has been similar to proton pump inhibitor (PPI) therapy with a comparable safety profile [
         <a href="#rid61">
          61-63
         </a>
         ]. The PCAB vonoprazan has been approved for the prevention of NSAID-induced ulcers and treatment of peptic ulcer disease in Japan. Another PCAB, revaprazan, has been approved in Korea. Studies also suggest that vonoprazan may be more effective in combination with antibiotics for the eradication of
         <em>
          H. pylori
         </em>
         [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H886298501">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H62689868">
         <span class="h2">
          Pregnancy and lactation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All histamine-2 receptor antagonists (H2RAs) appear to be safe in pregnancy, with
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         having the most safety data available [
         <a href="#rid66">
          66
         </a>
         ]. Cimetidine is concentrated in breast milk but is compatible with breastfeeding.
        </p>
        <p>
         Experience with proton pump inhibitors (PPIs) suggests that PPIs are safe in pregnancy [
         <a href="#rid67">
          67-69
         </a>
         ].
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          Omeprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         are secreted in low concentrations in breast milk [
         <a href="#rid70">
          70,71
         </a>
         ]. However, a large portion of them is likely to be destroyed by gastric acid in the infant's stomach [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Pregnancy and lactation'
         </a>
         .)
        </p>
        <p>
         Most antacids are considered safe in pregnancy and are compatible with breastfeeding [
         <a href="#rid73">
          73
         </a>
         ]. However, antacids containing
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         and magnesium trisilicate should be avoided in pregnancy [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Antacids'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          Sucralfate
         </a>
         is likely safe during pregnancy and lactation because it is poorly absorbed [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Prostaglandins of the E group are uterotropic.
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          Misoprostol
         </a>
         has been given with or without
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         to induce abortion [
         <a href="#rid69">
          69,72
         </a>
         ]. As a result, it is contraindicated in women of childbearing potential who are not on contraception. All patients should be informed of this risk to minimize the drug being inadvertently given by the patient to a pregnant woman.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eradication of
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ), withdrawal of nonsteroidal anti-inflammatory drugs (NSAIDs), and antisecretory drugs are the mainstays of treatment for peptic ulcer disease. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histamine-2 receptor antagonists (H2RAs) inhibit acid secretion by blocking H2 receptors on the parietal cell  (
         <a class="graphic graphic_figure graphicRef57131" href="/z/d/graphic/57131.html" rel="external">
          figure 1
         </a>
         ). Proton pump inhibitors (PPIs) effectively block acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. (See
         <a class="local">
          'Histamine-2 receptor antagonists'
         </a>
         above and
         <a class="local">
          'Proton pump inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PPI use results in faster control of peptic ulcer disease symptoms and higher ulcer healing rates as compared with H2RAs. PPIs are also more effective in preventing NSAID-induced gastroduodenal toxicity and in healing gastroduodenal ulcers associated with NSAIDs when they cannot be discontinued. PPIs are a component of
         <em>
          H. pylori
         </em>
         antibiotic regimens and are used in the management of hypersecretory states (eg, Zollinger-Ellison syndrome). The use of H2RAs is largely limited to the management of mild gastroesophageal reflux disease. (See
         <a class="local">
          'Indications and comparative efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antacids and
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         have no role in the treatment of peptic ulcer disease. The role of bismuth preparations (eg, bismuth subcitrate and
         <a class="drug drug_general" data-topicid="101044" href="/z/d/drug information/101044.html" rel="external">
          bismuth subsalicylate
         </a>
         ) is as part of a quadruple antibiotic therapy regimen in
         <em>
          H. pylori-
         </em>
         positive ulcers. (See
         <a class="local">
          'Antacids'
         </a>
         above and
         <a class="local">
          'Sucralfate'
         </a>
         above and
         <a class="local">
          'Bismuth'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prostaglandin analogues (eg,
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ) are effective for preventing NSAID-induced ulcers, but they have no established role for healing ulcers. Misoprostol is contraindicated in women of childbearing potential who are not on contraception. (See
         <a class="local">
          'Misoprostol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potassium-competitive acid inhibitors (PCABs) work by competing for potassium on the luminal side of the parietal cell, and cause rapid and reversible inhibition of pumps and therefore acid secretion. PCABs are not widely available outside of Asia, and data on safety and comparative efficacy with antisecretory agents are limited.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14518767">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Andrew H. Soll, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. N Engl J Med 1990; 323:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manlucu J, Tonelli M, Ray JG, et al. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nephrol Dial Transplant 2005; 20:2376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladziwa U, Koltz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994; 27:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JH. Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 1987; 82:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12 Suppl 2:S54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983; 308:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy DM. Ranitidine or cimetidine. Ann Intern Med 1983; 99:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potter HP Jr, Byrne EB, Lebovitz S. Fever after cimetidine and ranitidine. J Clin Gastroenterol 1986; 8:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano T, Kuroiwa T, Tsumita Y, et al. Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient. Clin Exp Nephrol 2004; 8:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takami N, Yamamoto Y, Matsuo H, et al. Agranulocytosis possibly caused by ranitidine in a patient with renal failure. Int J Clin Pharmacol Ther 2002; 40:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecker RD, Wijdicks EF, Wix K, McClelland R. Does famotidine induce thrombocytopenia in neurosurgical patients? J Neurosurg Anesthesiol 2004; 16:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases (2). N Engl J Med 1990; 323:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smallwood RA, Berlin RG, Castagnoli N, et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995; 40:63S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar A. Cimetidine: an immunomodulator. DICP 1990; 24:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantú TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991; 114:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Einsiedel RW, Roesch-Ely D, Diebold K, et al. H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. Pharmacopsychiatry 2002; 35:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanlon JT, Landerman LR, Artz MB, et al. Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf 2004; 13:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black M. Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists. Am J Med 1987; 83:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher AA, Le Couteur DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf 2001; 24:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinrichsen H, Halabi A, Kirch W. Clinical aspects of cardiovascular effects of H2-receptor antagonists. Eur J Clin Invest 1995; 25 Suppl 1:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KW, Kayser SR, Hongo RH, et al. Famotidine and long QT syndrome. Am J Cardiol 2004; 93:1325.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA news release. FDA requests removal of all ranitidine products (zantac) from the market. Available at: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market (Accessed on April 01, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000; 160:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl 1995; 210:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konturek SJ. New aspects of clinical pharmacology of antacids. J Physiol Pharmacol 1993; 44:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarnawski A, Hollander D, Gergely H. Antacids: new perspectives in cytoprotection. Scand J Gastroenterol Suppl 1990; 174:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weberg R, Berstad K, Berstad A. Acute effects of antacids on gastric juice components in duodenal ulcer patients. Eur J Clin Invest 1990; 20:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orwoll ES. The milk-alkali syndrome: current concepts. Ann Intern Med 1982; 97:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields HM. Rapid fall of serum phosphorus secondary to antacid therapy. Gastroenterology 1978; 75:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee S, El-Omar E, Mowat A, et al. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology 1996; 110:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blum AL, Bethge H, Bode JC, et al. Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study. Gut 1990; 31:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson JA, Salusky IB, Goodman WG, et al. Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. Ann Intern Med 1989; 111:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arieff AI, Cooper JD, Armstrong D, Lazarowitz VC. Dementia, renal failure, and brain aluminum. Ann Intern Med 1979; 90:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int 1990; 47:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990; 99:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron JH, Barr J, Batten J, et al. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 1986; 27:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo J, Ho J, Lam SK, et al. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 1982; 82:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elder JB. Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl 1986; 122:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nwokolo CU, Gavey CJ, Smith JT, Pounder RE. The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1989; 3:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nwokolo CU, Prewett EJ, Sawyer AM, et al. Lack of bismuth absorption from bismuth subnitrate (Roter) tablets. Eur J Gastroenterol Hepatol 1990; 2:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nwokolo CU, Prewett EJ, Sawyerr AM, et al. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology 1991; 101:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweeney JD, Hoernig LA. Hemostatic effects of salsalate in normal subjects and patients with hemophilia A. Thromb Res 1991; 61:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh BJ, McLaren M, Russell RI, et al. Comparison of the effect of aspirin and choline magnesium trisalicylate on thromboxane biosynthesis in human platelets: role of the acetyl moiety. Haemostasis 1989; 19:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen A. Fecal blood loss and plasma salicylate study of salicylsalicylic acid and aspirin. J Clin Pharmacol 1979; 19:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torgyán S, Ady E, Wagner L, et al. Reduction of indomethacin-induced gastrointestinal blood loss by sodium salicylate in man. Int J Clin Pharmacol Biopharm 1978; 16:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MC, Amirian DA, Toomey M, et al. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology 1988; 94:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman M. Prostaglandins and gastric ulcers: from seminal vesicle to misoprostol (Cytotec). Am J Med Sci 1990; 300:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi Porro G, Parente F. Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience. Scand J Gastroenterol Suppl 1989; 164:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnock-Jones KP. Vonoprazan: first global approval. Drugs 2015; 75:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007; 321:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018; 67:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 2017; 45:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018; 67:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017; 46:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larson JD, Patatanian E, Miner PB Jr, et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997; 90:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010; 363:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol 1998; 12:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plante L, Ferron GM, Unruh M, Mayer PR. Excretion of pantoprazole in human breast. J Reprod Med 2004; 49:825.
          </a>
         </li>
         <li class="breakAll">
          National Health Service. Proton-pump-inhibitors for treatment of reflux in a breastfeeding mother: which is preferred? https://www.evidence.nhs.uk/search?q=%22Proton-pump-inhibitors+for+treatment+of+reflux+in+a+breastfeeding+mother%22 (Accessed on March 13, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgkinson R, Glassenberg R, Joyce TH 3rd, et al. Comparison of cimetidine (Tagamet) with antacid for safety and effectiveness in reducing gastric acidity before elective cesarean section. Anesthesiology 1983; 59:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witter FR, King TM, Blake DA. The effects of chronic gastrointestinal medication on the fetus and neonate. Obstet Gynecol 1981; 58:79S.
          </a>
         </li>
         <li class="breakAll">
          Physician's Desk Reference, 46th ed, Physician's Desk Reference, Oradell, NJ 1992.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 32 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1978250" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16091377" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7851056" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2889354" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hepatic effects of drugs used in the treatment of peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2246495" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The clinical importance of drug interactions with antiulcer therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6835285" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6312863" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ranitidine or cimetidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24327038" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3734359" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fever after cimetidine and ranitidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15235935" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12698989" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Agranulocytosis possibly caused by ranitidine in a patient with renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15557833" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Does famotidine induce thrombocytopenia in neurosurgical patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1978926" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases (2)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7859585" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Safety of acid-suppressing drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2138376" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cimetidine: an immunomodulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1674198" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Central nervous system reactions to histamine-2 receptor blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12163986" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15386717" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2892410" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11219486" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7781677" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical aspects of cardiovascular effects of H2-receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15135720" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Famotidine and long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15135720" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Famotidine and long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28528705" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Complications of Proton Pump Inhibitor Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2142113" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2151756" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The relationship between suppression of acidity and gastric ulcer healing rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2643037" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10826458" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8578218" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8260735" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : New aspects of clinical pharmacology of antacids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2205902" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Antacids: new perspectives in cytoprotection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2124982" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acute effects of antacids on gastric juice components in duodenal ulcer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7049033" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The milk-alkali syndrome: current concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/710865" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rapid fall of serum phosphorus secondary to antacid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987878" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nonsteroidal anti-inflammatory drugs and peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8608880" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2196208" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2742249" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/434672" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Dementia, renal failure, and brain aluminum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2257522" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2199292" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bismuth therapy in gastrointestinal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3084345" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7060908" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3535016" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21345487" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3053124" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2491456" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lack of bismuth absorption from bismuth subnitrate (Roter) tablets
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1889712" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2020937" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hemostatic effects of salsalate in normal subjects and patients with hemophilia A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2744633" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of the effect of aspirin and choline magnesium trisalicylate on thromboxane biosynthesis in human platelets: role of the acetyl moiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/312297" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Fecal blood loss and plasma salicylate study of salicylsalicylic acid and aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/365801" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Reduction of indomethacin-induced gastrointestinal blood loss by sodium salicylate in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2832242" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1976294" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prostaglandins and gastric ulcers: from seminal vesicle to misoprostol (Cytotec).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2510273" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2904006" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16000224" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25744862" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vonoprazan: first global approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17369284" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Soraprazan: setting new standards in inhibition of gastric acid secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28988197" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27891632" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29196436" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26935876" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28497487" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207819" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21105793" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19491869" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22038541" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The safety of fetal exposure to proton-pump inhibitors during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9582548" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15568407" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Excretion of pantoprazole in human breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15568407" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Excretion of pantoprazole in human breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6869899" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Comparison of cimetidine (Tagamet) with antacid for safety and effectiveness in reducing gastric acidity before elective cesarean section.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7031544" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The effects of chronic gastrointestinal medication on the fetus and neonate.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
